Cocrystal Pharma, Inc.

Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results

Completed dosing in Phase 1b challenge study of CDI-988 for norovirus prevention and treatment with no serious adverse events reportedPreliminary efficacy results expected near the end of 2026 Closed $5 million private placement with OPKO HealthAppointed antiviral drug development leader Carol Brosgart, MD, to the Board of DirectorsBOTHELL, Wash., Nov. 15, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ('Cocrystal” or the 'Company”) provides updates on its antiviral product pipeline and business activities and reports financial results for the three and nine months ended September 30, 2026.